Nanoparticulate chitosan-TNF-α-VLPs activate mast cells and enhance adaptive immunity induced by foot-and-mouth disease virus-like particles in mice

IF 1.4 3区农林科学 Q4 IMMUNOLOGY

Veterinary immunology and immunopathology Pub Date : 2023-10-01 DOI:10.1016/j.vetimm.2023.110662

Ruoman Bai , Mingzhu Li , Zhanyun Tian , Yiming Hu , Manxin An , Wanzhe Yuan , Limin Li

{"title":"Nanoparticulate chitosan-TNF-α-VLPs activate mast cells and enhance adaptive immunity induced by foot-and-mouth disease virus-like particles in mice","authors":"Ruoman Bai , Mingzhu Li , Zhanyun Tian , Yiming Hu , Manxin An , Wanzhe Yuan , Limin Li","doi":"10.1016/j.vetimm.2023.110662","DOIUrl":null,"url":null,"abstract":"<div><p>Chitosan nanoparticulate vaccines have attracted considerable attention to potentiate immune responses. A chitosan-TNF-α-VLPs nanoparticle vaccine against foot-and-mouth disease virus (FMDV) prepared though inotropic gelation method and whether this nanoparticulate vaccine can activate mast cells and enhance immune responses induced by FMDV virus-like particles (VLPs) in mice was investigated. The nanoparticle was approximately spherical, and its size was approximately 200–300 nm. Following immunization via subcutaneous injection, the chitosan-TNF-α-VLPs nanoparticles could induce higher levels of FMDV-specific antibodies and stimulation index value than VLPs only (<em>P</em> < 0.01) and had similar levels to commercial vaccine group and VLPs+adjuvant group (<em>P</em> > 0.05). No significant differences were observed in the concentrations of IL-4, IFN-γ and IL-10 among the chitosan-TNF-α-VLPs group, VLPs+adjuvant group and commercial vaccine group (<em>P</em> > 0.05). Of note, the chitosan-TNF-α-VLPs nanoparticles can effectively activate mast cells in lymph nodes. These results indicated that the chitosan-TNF-α-VLPs nanoparticles can enhance both humoral and cell-mediated immunity, and both Th1 and Th2 responses, even activate mast cells, demonstrating that chitosan-TNF-α nanoparticles are potential as a vaccine adjuvant to enhance immune responses induced by FMDV-VLPs.</p></div>","PeriodicalId":23511,"journal":{"name":"Veterinary immunology and immunopathology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary immunology and immunopathology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165242723001162","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chitosan nanoparticulate vaccines have attracted considerable attention to potentiate immune responses. A chitosan-TNF-α-VLPs nanoparticle vaccine against foot-and-mouth disease virus (FMDV) prepared though inotropic gelation method and whether this nanoparticulate vaccine can activate mast cells and enhance immune responses induced by FMDV virus-like particles (VLPs) in mice was investigated. The nanoparticle was approximately spherical, and its size was approximately 200–300 nm. Following immunization via subcutaneous injection, the chitosan-TNF-α-VLPs nanoparticles could induce higher levels of FMDV-specific antibodies and stimulation index value than VLPs only (P < 0.01) and had similar levels to commercial vaccine group and VLPs+adjuvant group (P > 0.05). No significant differences were observed in the concentrations of IL-4, IFN-γ and IL-10 among the chitosan-TNF-α-VLPs group, VLPs+adjuvant group and commercial vaccine group (P > 0.05). Of note, the chitosan-TNF-α-VLPs nanoparticles can effectively activate mast cells in lymph nodes. These results indicated that the chitosan-TNF-α-VLPs nanoparticles can enhance both humoral and cell-mediated immunity, and both Th1 and Th2 responses, even activate mast cells, demonstrating that chitosan-TNF-α nanoparticles are potential as a vaccine adjuvant to enhance immune responses induced by FMDV-VLPs.

Abstract Image

查看原文本刊更多论文

纳米壳聚糖TNF-α-VLP激活小鼠肥大细胞，增强口蹄疫病毒样颗粒诱导的适应性免疫。

壳聚糖纳米粒子疫苗在增强免疫反应方面引起了人们的极大关注。采用嗜力凝胶法制备了一种壳聚糖TNF-α-VLPs纳米粒子口蹄疫病毒疫苗，并研究了该纳米粒子疫苗是否能激活肥大细胞，增强口蹄疫病毒样颗粒（VLPs）诱导的小鼠免疫反应。纳米颗粒近似为球形，其尺寸约为200-300nm。经皮下注射免疫后，壳聚糖TNF-α-VLPs纳米粒子可诱导比仅VLPs更高水平的FMDV特异性抗体和刺激指标值（P 0.05）。壳聚糖TNF--α-VLPs组、VLP+佐剂组和市售疫苗组的IL-4、IFN-γ和IL-10浓度无显著差异（P＞0.05），α-VLPs纳米粒子能有效激活淋巴结肥大细胞。这些结果表明，壳聚糖TNF-α-VLP纳米颗粒可以增强体液和细胞介导的免疫，以及Th1和Th2反应，甚至激活肥大细胞，表明壳聚糖TNF-α纳米颗粒有可能作为疫苗佐剂增强FMDV VLPs诱导的免疫反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary immunology and immunopathology 农林科学-免疫学

CiteScore

3.40

自引率

5.60%

发文量

审稿时长

70 days

期刊介绍： The journal reports basic, comparative and clinical immunology as they pertain to the animal species designated here: livestock, poultry, and fish species that are major food animals and companion animals such as cats, dogs, horses and camels, and wildlife species that act as reservoirs for food, companion or human infectious diseases, or as models for human disease. Rodent models of infectious diseases that are of importance in the animal species indicated above,when the disease requires a level of containment that is not readily available for larger animal experimentation (ABSL3), will be considered. Papers on rabbits, lizards, guinea pigs, badgers, armadillos, elephants, antelope, and buffalo will be reviewed if the research advances our fundamental understanding of immunology, or if they act as a reservoir of infectious disease for the primary animal species designated above, or for humans. Manuscripts employing other species will be reviewed if justified as fitting into the categories above. The following topics are appropriate: biology of cells and mechanisms of the immune system, immunochemistry, immunodeficiencies, immunodiagnosis, immunogenetics, immunopathology, immunology of infectious disease and tumors, immunoprophylaxis including vaccine development and delivery, immunological aspects of pregnancy including passive immunity, autoimmuity, neuroimmunology, and transplanatation immunology. Manuscripts that describe new genes and development of tools such as monoclonal antibodies are also of interest when part of a larger biological study. Studies employing extracts or constituents (plant extracts, feed additives or microbiome) must be sufficiently defined to be reproduced in other laboratories and also provide evidence for possible mechanisms and not simply show an effect on the immune system.